Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Lowered by Wall Street Zen

Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other equities analysts have also commented on ALNY. Chardan Capital cut their price objective on shares of Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating for the company in a research report on Friday, February 13th. Wells Fargo & Company decreased their target price on shares of Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating on the stock in a report on Tuesday, January 20th. Bank of America reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. Raymond James Financial reissued an “outperform” rating and issued a $472.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, January 12th. Finally, HC Wainwright restated a “buy” rating and set a $510.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, February 18th. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $468.84.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $312.17 on Friday. The business’s fifty day moving average is $335.41 and its 200 day moving average is $404.77. The firm has a market cap of $41.40 billion, a price-to-earnings ratio of 182.56 and a beta of 0.36. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76. Alnylam Pharmaceuticals has a 52-week low of $205.87 and a 52-week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company had revenue of $1.10 billion during the quarter, compared to the consensus estimate of $1.16 billion. During the same quarter in the prior year, the business earned ($0.65) EPS. The firm’s revenue for the quarter was up 84.9% compared to the same quarter last year. Research analysts predict that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Activity at Alnylam Pharmaceuticals

In related news, EVP Jeffrey V. Poulton sold 2,780 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $1,008,778.60. Following the sale, the executive vice president directly owned 57,465 shares of the company’s stock, valued at $20,852,324.55. This trade represents a 4.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 2,290 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $370.33, for a total transaction of $848,055.70. Following the sale, the executive vice president owned 21,264 shares of the company’s stock, valued at approximately $7,874,697.12. The trade was a 9.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 53,923 shares of company stock valued at $18,072,087 in the last ninety days. 1.20% of the stock is currently owned by company insiders.

Institutional Trading of Alnylam Pharmaceuticals

A number of hedge funds have recently made changes to their positions in ALNY. Brighton Jones LLC bought a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $243,000. Geneos Wealth Management Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 372.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 175 shares in the last quarter. Cetera Investment Advisers raised its holdings in shares of Alnylam Pharmaceuticals by 23.3% during the 2nd quarter. Cetera Investment Advisers now owns 9,888 shares of the biopharmaceutical company’s stock valued at $3,224,000 after buying an additional 1,871 shares in the last quarter. Ensign Peak Advisors Inc lifted its position in Alnylam Pharmaceuticals by 24.5% in the 2nd quarter. Ensign Peak Advisors Inc now owns 100,209 shares of the biopharmaceutical company’s stock worth $32,677,000 after buying an additional 19,730 shares during the last quarter. Finally, Prudential PLC lifted its position in Alnylam Pharmaceuticals by 100.9% in the 2nd quarter. Prudential PLC now owns 4,112 shares of the biopharmaceutical company’s stock worth $1,341,000 after buying an additional 2,065 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.